UPMC and University of Pittsburgh launched an advanced genome sequencing center, which aims to support the advancement of precision medicine and immunotherapy.
The UPMC Genome Center is a large-scale genomics facility that has undergone validation testing and has obtained Clinical Laboratory Improvement Amendments certification. It gives clinicians and researchers access to whole genome sequencing capabilities. It features five next-generation NovaSeq 6000 Systems for automated sample preparation and processing.
Initially, researchers from UPMC Immune Transplant and Therapy Center will use the center to study whether whole genome sequencing can be used to diagnose critically ill infants at the Children's Hospital of Pittsburgh of UPMC. Additionally, 600 cancer patients undergoing immunotherapy at the UPMC Hillman Cancer Center will also gain access to whole genome sequencing to help inform their treatment.
"The Genome Center provides researchers and physicians with access to a world-class genomics infrastructure that they previously had to outsource to other companies or institutions outside of this region," said Annerose Berndt, PhD, director of the genome center.